Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination
Mawaddah Alislambouli, Andy Veras Victoria, Jyoti Matta, Fang Yin
Abstract
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease and has occasionally been described after vaccination, especially against viral agents. We present a case of a patient who presents with the classic pentad of TTP a few days after receiving the first dose of the mRNA Pfizer COVID-19 vaccine. To our knowledge, this is the second report of a de novo TTP following mRNA Pfizer COVID-19 vaccination.
Topics & Concepts
Thrombotic thrombocytopenic purpuraMedicineCoronavirus disease 2019 (COVID-19)VaccinationVirology2019-20 coronavirus outbreakThrombocytopenic purpuraImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Purpura (gastropod)PediatricsPlateletInternal medicineOutbreakBiologyInfectious disease (medical specialty)DiseaseEcologyComplement system in diseasesHeparin-Induced Thrombocytopenia and ThrombosisPlatelet Disorders and Treatments